A Cleveland Clinic study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) ...

Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

The number one unmet need is that we don't have a good handle on who's at risk, because patients generally don't have too ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and ...

The patients studied on the medical wards of the Boston City Hospital had been admitted primarily for treatment of severe liver disease ... in the southwestern United States and in 3.5 per cent ...

The scoring method, called the Tumor Immune Microenvironment Spatial System, or TIMES, is the first tool in the world to ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.

Lipocine announces US FDA labelling changes for testosterone products: Salt Lake City Thursday, March 13, 2025, 16:00 Hrs [IST] Lipocine Inc., a biopharmaceutical company leveragi ...

Chinese scientists and their Singaporean collaborators have developed a scoring system to predict the risk of recurrence for ...